Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer.
Although reduction in the serum prostate specific antigen (PSA) correlates with clinical outcome for high dose rate Iridium-192 (HDR Ir-192) brachytherapy, it takes a long latency period. We investigated numerical chromosome changes of prostatic cancer during the pre- and post-treatment periods of HDR Ir-192 brachytherapy (and external beam radiotherapy), using fluorescence in situ hybridization (FISH) to clear the effect of treatment in early phase. Transitional changes in the frequency of aneuploidy for chromosomes 7, 8, 10, 12, 16, X, and Y in prostate cancer during the pre- and post-treatment periods were observed. Gains of chromosomes 7, 8 and 12 were noted in the pre-treatment samples (4 out of 12 cases in chromosomes 7 and 8; 1 out of 12 cases in chromosome 12), while a notable reduction in the number of cells with extra copies of these chromosomes was observed in post-treatment specimens. This change appears earlier than the reduction in the value of prostate specific antigen (PSA) and strongly reflects the effect of HDR brachytherapy with external beam radiotherapy in localized prostate cancer. Decrease in the number of cells with high ploidies of chromosomes 7, 8 and 12 at 12 weeks after treatment may predict clinical effects of radiation therapy, which may explain the radiation dependency of localized prostate cancer cells.
Kasahara
K
K
Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan. kasahara@med.kochi-ms.ac.jp
Taguchi
T
T
Inoue
K
K
Shuin
T
T
Kariya
S
S
Yoshida
S
S
Furihata
M
M
D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D001918:Brachytherapy / Q000379:methods*; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics* / Q000528:radiation effects; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics* / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000235:genetics / Q000532:radiotherapy*; D013997:Time Factors; D016896:Treatment Outcome
D007496:Iridium Radioisotopes; D017430:Prostate-Specific Antigen